Sequence: Multicomponent peptide (poly-L-lysine dendron + GALA + TAT) with stearic acid (STR) on C-terminal Lys side chain
| Experiment Id | EXP001186 |
|---|---|
| Paper | Design and evaluation of a stearylated multicomponent peptide-siRNA nanocomplex for efficient cellul |
| Peptide | DEN-K(GALA)-TAT-K(STR) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | Peptide/siRNA molar ratios tested 25–125 (uptake/knockdown); 50–200 for DLS; complexes formed in 20 mM HEPES pH 7.2, 30 min RT |
| Rna Concentration | 20 nM siRNA (uptake/knockdown assays); 10 nM Alexa488-siRNA for confocal trafficking; 100 ng siRNA for gel shift |
| Mixing Ratio | Peptide:siRNA molar ratio (optimal ~100 for compact particles and knockdown) |
| Formulation Format | Electrostatic peptide/siRNA nanocomplex (nanoparticle) |
| Formulation Components | DEN-K(GALA)-TAT-K(STR) + eGFP siRNA in 20 mM HEPES buffer pH 7.2 (30 min incubation) |
| Size Nm | 92.50 |
| Zeta Mv | 44.20 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Stable eGFP-expressing HeLa cells |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro functional RNA effect (eGFP knockdown at protein and mRNA levels) |
| Output Value | ~58% reduction in eGFP protein at molar ratio 100 (48 h); ~57% decrease in eGFP mRNA (qRT-PCR) |
| Output Units | |
| Output Notes | Enhanced uptake vs non-lipidic analog; compact ~100 nm positively charged particles; best knockdown at molar ratio 100 with no further improvement at 125. |
| Toxicity Notes | Low cytotoxicity under assay conditions (∼15% viability loss at 2 µM vector with 20 nM siRNA); less toxic than 25 kDa bPEI control. |
| Curation Notes |